BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020.

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement with institutional investors to purchase an aggregate of 9,569,430 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase an aggregate of 5,780,537 shares of common stock,

SeaStar Medical Foundation receives 501(c)(3) Certificate from the IRS, launches mission to accelerate medical discovery in unmet orphan markets.

Inspired Spine has released an innovative study presenting the use of Porcine Cadavers as an Alternative to Human Cadavers for Teaching Minimally Invasive Spinal Fusion: Proof of Concept and Anatomical Comparison.

A strong recurring message of individualizing patient care is echoed throughout the American Diabetes Association’s Standards of Medical Care in Diabetes—2020 (Standards of Care) published today.

iView Therapeutics Inc. today announced that the first patient has been dosed in the Phase 2 IVIEW-1201-01-AIC clinical trial program assessing the efficacy of IVIEW-1201 in patients (age ≥15 years) with Acute Adenoviral Conjunctivitis. First subject was dosed on 19 Dec in India at Disha Eye Hospital Pvt. Ltd. Kolkata under this Phase II Clinical trial program.

Fertilizer Canada, in partnership with the Paramedic Association of Canada, Canadian Association of Fire Chiefs and the Canadian Association of Chiefs of Police, launched an update of the Anhydrous Ammonia Awareness for First Responders awareness program, which gives the first responder community educational resources they need to understand the use and handling of agricultural anhydrous ammonia.

Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the closing of its public offering of 10,263,750 shares of its common stock at a public offering price of $8.40 per share,

The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has opened a new fund to provide copayment and premium assistance to Medicare patients living with chronic heart failure.

On December 17th, Health Canada formally indicated that they have found “Zopiclone impurity 22" in some batches of the U-Dream product.